FDA Approves Eye Drops To Help With Blurry Vision 

The pharmaceutical company AbbVie has unveiled their latest medical product called Vuity, eye drops that can help improve symptoms of presbyopia (age-related blurry vision). 

A new prescription eye drop medication to help with age-related blurry vision was approved by the Federal Drug Administration (FDA)and can also act as a solution for the need for reading glasses in certain cases. The prescription eye drops called Vuity are now available in the U.S.that can help improve users’ vision to see things up close.
 
The US Food and Drug Administration (USDA) approved Vuity in October 2021 with the eye drops that treat age-related blurry near vision also known as presbyopia. This conditional on average starts after the age of 40 as people start having trouble with blurry vision while trying to focus on an object close to them.
 
The creator of Vuity is the pharmaceutical company Allergan that is owned by the biopharmaceutical company AbbVie that is a spin-off of Abbott Laboratories. Allergan has some edge over the competition developing the first and only eye drop to treat presbyopia to be approved by the FDA.
 
Allergan discloses Vuity eye drops works by restricting the pupil size using a formula containing pilocarpine that is also a key ingredient for other medications for eye treatment. Vuity claims the eye drops can start working 15 minutes after the administered doses that don’t impact distance vision and can last for up to six hours.
 
AbbVie disclosed that Vuity isn’t a replacement for reading glasses also stressing that this medication won’t help with other vision medical conditions like hyperopia (farsightedness) or myopia (nearsightedness)that have similar symptoms of presbyopia. According to an AbbVie spokesperson,the average cost of this treatment for patients will be $79 for a 30-day supply with a 2.5-milliliter bottle though there are other factors such as insurance coverage or pharmacy that can change the average price.
 
Vuity conducted a clinical study that was presented to the FDA for approval consisting of 750 participants ages 40 to 55 diagnosed with presbyopia. Participants of the study receiving Vuity compared to the placebo group presented “a statistically significant proportion of patients” that we’re able to read three or more additional lines on a reading chart.
 

Vuity is now available in pharmacies nationwide with a prescription and if you’re considering looking into using Vuity, it’s recommended to consult a qualified health provider. This article is educational and is strictly for informational purposes that is not intended as medical advice.